September 2026

AOD-9604 landed on the WADA 2026 Prohibited List — and the FDA closed the compounding door in the same window

Two regulatory moves hit AOD-9604 in 2026 that the fat-loss peptide community has not fully absorbed together. The 2026 WADA Prohibited List added it to the banned substance register — the same one governing what athletes in governed sport can and cannot have in their systems. Then, by June 2026, the FDA’s compounding evaluation process recorded AOD-9604 as Nominated but Withdrawn, meaning it is no longer under active Category 2 consideration and licensed compounding pharmacies no longer have a regulatory pathway to prepare it under 503A or 503B frameworks. Banned in sport. Locked out of compounding. Still available on unlicensed online marketplaces operating entirely outside FDA oversight. Monthly search volume has not meaningfully declined. Wellness content continues describing it as a cleaner fat-burning alternative to exogenous growth hormone, and some clinics are still offering it under informal sourcing arrangements that predate the withdrawal. What those promotions routinely omit is the human clinical program that Metabolic Pharmaceuticals ran almost 20 years ago — and the decision they reached in March 2007 after looking at the Phase 2b data.

The actual molecule

it’s a fragment of human growth hormone — the part the lipolysis claim is built around

AOD-9604 was developed as a synthetic analog of the C-terminal region of human growth hormone, specifically amino acids 176 through 191 of the HGH sequence. The design rationale was straightforward: the full GH molecule produces both fat-mobilizing effects and anabolic effects tied to IGF-1 axis stimulation. If a fragment could retain the lipolytic activity while bypassing the tissue-growth and glucose-handling disruptions of full GH, you would have a theoretically useful obesity compound without the full hormonal footprint. AOD stood for anti-obesity drug in Metabolic Pharmaceuticals’ nomenclature. [PubMed literature on AOD-9604](https://pubmed.ncbi.nlm.nih.gov/?term=AOD-9604) covers the mechanistic hypothesis: β3-adrenergic receptor-like activity, stimulation of lipolysis in adipose tissue, and inhibition of lipogenesis in cell models. That mechanism is real biology. Whether it translates to meaningful, durable fat loss in people at clinically relevant doses is a separate question — and it is exactly the question the clinical trials were designed to answer.

The fat-loss pitch

clinics sold it as the cleaner GH alternative — and the WADA ban made the marketing louder

The wellness frame for AOD-9604 in September 2026 is nearly identical to what Metabolic Pharmaceuticals pitched before their trials ran. It targets fat without disrupting insulin or raising IGF-1. It lacks the joint pain, water retention, and blood sugar effects that exogenous GH can produce. For people who want the lipolysis upside of GH-axis compounds without the hormonal tradeoffs, that pitch lands. Some clinics positioned AOD-9604 alongside GLP-1 protocols, promoting it as a stacking partner that could accelerate body composition changes that semaglutide-based regimens do not fully address. The WADA ban has added a perverse marketing wrinkle: if athletic governing bodies prohibit it, the logic goes, it must work well enough to matter. That reasoning deserves engagement with the clinical record before it circulates further. WADA’s Prohibited List operates on mechanism-based precautionary logic — compounds with lipolytic or body-composition potential get flagged regardless of whether human trials confirmed that potential at meaningful scale.

What the data says

a 12-week trial showed promise, then the 24-week Phase 2b trial in 536 subjects came back flat

The human clinical record for AOD-9604 as an obesity drug is short, complete, and conclusive. Metabolic Pharmaceuticals ran two rounds of human trials. An early 12-week trial produced a finding that justified continuing: subjects taking AOD-9604 lost approximately 2.6 kg compared to 0.8 kg in the placebo arm — a separation that looked real and worth pursuing. [A 2004 report from News-Medical](https://www.news-medical.net/news/2004/12/16/6878.aspx) captured the early optimism from Metabolic Pharmaceuticals as the program moved forward. Then came the definitive test. The Phase 2b trial enrolled 536 obese subjects across 24 weeks, randomized across three dose levels versus placebo. None of the treatment arms demonstrated statistically significant weight loss compared to placebo. Not at any dose. Metabolic Pharmaceuticals terminated the anti-obesity drug program in March 2007. [A PMC review of anti-obesity pharmacotherapy](https://pmc.ncbi.nlm.nih.gov/articles/PMC3136748/) places AOD-9604 among the peptide candidates that showed mechanistic promise and clinical underperformance — a common enough pattern in this category. [Active ClinicalTrials.gov registrations for AOD-9604](https://clinicaltrials.gov/search?term=AOD-9604) show limited modern trial activity. The development file that closed in 2007 has not meaningfully reopened.

Early human — PeptideFactCheck stance

terminated in 2007, banned in sport in 2026, and still circulating on unlicensed peptide websites

AOD-9604 holds PeptideFactCheck’s Early human tier: interesting enough to watch, too early for broad certainty. In this case, the human data exists — a real Phase 2b program in 536 subjects — and it came back flat on its primary endpoint. The development terminated in 2007 and has not been revived. What 2026 added is regulatory texture in both directions. WADA’s Prohibited List entry treats it as a compound capable of affecting body composition in athletes, a mechanism-based precautionary judgment that does not require confirmed clinical outcomes. The FDA compounding withdrawal removes the licensed domestic access pathway without making a positive therapeutic finding either way. Two different regulatory agencies reached conclusions that do not fully harmonize with each other or with the clinical trial record. [The FDA bulk drug substances page](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) documents where the compounding posture stands. For anyone tracking the fat-loss peptide market in 2026, AOD-9604 is a useful data point: the mechanism was rational, the clinical program was appropriately sized, and the Phase 2b result was null. The internet’s appetite for the compound has outpaced the evidence record by nearly two decades. Source trail before certainty.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.